
Atriva Therapeutics gets €24m from EIB
According to Atriva Therapeutics, the proceeds allow the company to start Phase II testing of its oral MEK inhibitor ATR-002. In preclinical trails,...

Vifor Pharma in US$100m licence deal with Cara Therapeutics
Under the licence deal with the US company Cara Therapeutics Inc., Swiss Vifor Pharma has acquired the US commercialisation rights for intravenous...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Galecto raise US$85m in Nasdaq IPO
The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of...

Novo Holdings creates Hemab
Hemab ApS will combine antibody know-how from Genmab A/S and Novo Nordisk to fight medically underserved orphan bleeding disorders. The company...

Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Cancer antibody specialist BioInvent International AB has granted the exclusive rights to market its anti-FcγRIIB antibody, BI-1206, in China,...

Global bioeconomy in the spotlight
Whereas first editions of the summit took place in Berlin in 2015 and 2018, the third edition was organized as a digital conference week from 16th to...